Stryker Expands in Spine with Surgical Dynamics

With so much interesting technology in the spine market today, valuations are sky high. Stryker's $135 million deal for Surgical Dynamics raises eyebrows for its low price. But if it isn't the boldest move in spine, Stryker's deal could very turn out to be a very good one, as the company gains an important foothold in the spinal cage market.

On the face of it, Stryker Corp. 's purchase of spinal cage company Surgical Dynamics Inc. doesn't seem all that impressive [See Deal]. After all, Surgical Dynamics has been on the market with no takers for years, almost since the day its parent United States Surgical (now a division of Tyco Healthcare Group ) was acquired by Tyco International Ltd. in 1998 [See Deal]. And certainly foremost among the concerns of any potential acquirers had to be both the patent litigation that Surgical Dynamics was facing and, more generally, the disappointing fall-off of the spinal cage market beginning in the late 1990s. Indeed, Stryker's purchase price of $135 million pales before the valuations put on other innovative spinal companies: one month after its IPO, Kyphon Inc. 's market cap stood at $650 million [See Deal], while Oratec Interventions Inc. fetched $310 million in its recent deal with Smith & Nephew PLC [See Deal].

But people close to this deal say it may turn out to be a much better deal for Stryker than...

More from Archive

More from In Vivo

EU Medtech Outlook: The View From MedTech Europe Experts

 
• By 

MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.

‘Confident In Lorundrostat’s Promise’: Mineralys CEO Talks Trials And Next Steps

 

In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.

BioBytes: Qubit Pharmaceuticals Unveils Quantum AI Model For Drug Discovery

 
• By 

Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.